热休克蛋白90：临床试验中的抑制剂 - Suppr

Suppr

超能文献

Heat shock protein 90: inhibitors in clinical trials.

作者信息

Biamonte Marco A, Van de Water Ryan, Arndt Joseph W, Scannevin Robert H, Perret Daniel, Lee Wen-Cherng

机构信息

Biogen Idec, 5200 Research Place, San Diego, California 92122, USA.

出版信息

J Med Chem. 2010 Jan 14;53(1):3-17. doi: 10.1021/jm9004708.

DOI:10.1021/jm9004708

PMID:20055425

Abstract

摘要

相似文献

Heat shock protein 90: inhibitors in clinical trials.

J Med Chem. 2010 Jan 14;53(1):3-17. doi: 10.1021/jm9004708.

Discovery of a macrocyclic o-aminobenzamide Hsp90 inhibitor with heterocyclic tether that shows extended biomarker activity and in vivo efficacy in a mouse xenograft model.

Bioorg Med Chem Lett. 2011 Jun 15;21(12):3627-31. doi: 10.1016/j.bmcl.2011.04.102. Epub 2011 Apr 28.

Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90.

J Med Chem. 2006 Jul 27;49(15):4606-15. doi: 10.1021/jm0603116.

Synthesis and anticancer activity of geldanamycin derivatives derived from biosynthetically generated metabolites.

Org Biomol Chem. 2008 Jan 21;6(2):340-8. doi: 10.1039/b713407j. Epub 2007 Nov 30.

Purine-scaffold Hsp90 inhibitors.

IDrugs. 2006 Nov;9(11):778-82.

Molecular characterization of macbecin as an Hsp90 inhibitor.

J Med Chem. 2008 May 8;51(9):2853-7. doi: 10.1021/jm701558c. Epub 2008 Mar 22.

Structure-based and in silico design of Hsp90 inhibitors.

ChemMedChem. 2009 Sep;4(9):1399-409. doi: 10.1002/cmdc.200900256.

Optimizing natural products by biosynthetic engineering: discovery of nonquinone Hsp90 inhibitors.

J Med Chem. 2008 Sep 25;51(18):5494-7. doi: 10.1021/jm8006068.

Total synthesis of resorcinol amide Hsp90 inhibitor AT13387.

J Org Chem. 2012 Dec 21;77(24):11296-301. doi: 10.1021/jo302406w. Epub 2012 Dec 6.

Total synthesis of herbimycin A.

Org Lett. 2007 Jan 4;9(1):145-8. doi: 10.1021/ol062642i.

引用本文的文献

Advances in the structures, mechanisms and targeting of molecular chaperones.

Signal Transduct Target Ther. 2025 Mar 12;10(1):84. doi: 10.1038/s41392-025-02166-2.

Design, Synthesis, and Biological Evaluation of Chiral-Proline Derivatives as Novel HSP90 Inhibitors.

ACS Med Chem Lett. 2025 Jan 22;16(2):301-310. doi: 10.1021/acsmedchemlett.4c00550. eCollection 2025 Feb 13.

Thermal Titration Molecular Dynamics: The Revenge of the Fragments.

J Chem Inf Model. 2025 Feb 10;65(3):1492-1513. doi: 10.1021/acs.jcim.4c01681. Epub 2025 Jan 21.

Discovery of new Hsp90-Cdc37 protein-protein interaction inhibitors: screening and optimization of anticancer activity.

RSC Adv. 2024 Sep 5;14(39):28347-28375. doi: 10.1039/d4ra05878j. eCollection 2024 Sep 4.

Targeted delivery of HSP90 inhibitors for efficient therapy of CD44-positive acute myeloid leukemia and solid tumor-colon cancer.

J Nanobiotechnology. 2024 Apr 22;22(1):198. doi: 10.1186/s12951-024-02460-1.

Intrinsic Solubility of Ionizable Compounds from p Shift.

ACS Omega. 2023 Nov 13;8(47):44571-44577. doi: 10.1021/acsomega.3c04071. eCollection 2023 Nov 28.

Cascade Transformation of the Ansamycin Benzoquinone Core into Benzoxazole Influencing Anticancer Activity and Selectivity.

J Org Chem. 2023 Jul 7;88(13):9469-9474. doi: 10.1021/acs.joc.3c00493. Epub 2023 Jun 5.

The chaperone system in cancer therapies: Hsp90.

J Mol Histol. 2023 Apr;54(2):105-118. doi: 10.1007/s10735-023-10119-8. Epub 2023 Mar 18.

Impact of Co-chaperones and Posttranslational Modifications Toward Hsp90 Drug Sensitivity.

Subcell Biochem. 2023;101:319-350. doi: 10.1007/978-3-031-14740-1_11.

HSP90 inhibitors and cancer: Prospects for use in targeted therapies (Review).

Oncol Rep. 2023 Jan;49(1). doi: 10.3892/or.2022.8443. Epub 2022 Nov 11.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Heat shock protein 90: inhibitors in clinical trials.

作者信息

Biamonte Marco A, Van de Water Ryan, Arndt Joseph W, Scannevin Robert H, Perret Daniel, Lee Wen-Cherng

机构信息

Biogen Idec, 5200 Research Place, San Diego, California 92122, USA.

出版信息

J Med Chem. 2010 Jan 14;53(1):3-17. doi: 10.1021/jm9004708.

DOI:10.1021/jm9004708

PMID:20055425

Abstract

摘要

相似文献

Heat shock protein 90: inhibitors in clinical trials.

J Med Chem. 2010 Jan 14;53(1):3-17. doi: 10.1021/jm9004708.

Discovery of a macrocyclic o-aminobenzamide Hsp90 inhibitor with heterocyclic tether that shows extended biomarker activity and in vivo efficacy in a mouse xenograft model.

Bioorg Med Chem Lett. 2011 Jun 15;21(12):3627-31. doi: 10.1016/j.bmcl.2011.04.102. Epub 2011 Apr 28.

Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90.

J Med Chem. 2006 Jul 27;49(15):4606-15. doi: 10.1021/jm0603116.

Synthesis and anticancer activity of geldanamycin derivatives derived from biosynthetically generated metabolites.

Org Biomol Chem. 2008 Jan 21;6(2):340-8. doi: 10.1039/b713407j. Epub 2007 Nov 30.

Purine-scaffold Hsp90 inhibitors.

IDrugs. 2006 Nov;9(11):778-82.

Molecular characterization of macbecin as an Hsp90 inhibitor.

J Med Chem. 2008 May 8;51(9):2853-7. doi: 10.1021/jm701558c. Epub 2008 Mar 22.

Structure-based and in silico design of Hsp90 inhibitors.

ChemMedChem. 2009 Sep;4(9):1399-409. doi: 10.1002/cmdc.200900256.

Optimizing natural products by biosynthetic engineering: discovery of nonquinone Hsp90 inhibitors.

J Med Chem. 2008 Sep 25;51(18):5494-7. doi: 10.1021/jm8006068.

Total synthesis of resorcinol amide Hsp90 inhibitor AT13387.

J Org Chem. 2012 Dec 21;77(24):11296-301. doi: 10.1021/jo302406w. Epub 2012 Dec 6.

Total synthesis of herbimycin A.

Org Lett. 2007 Jan 4;9(1):145-8. doi: 10.1021/ol062642i.

引用本文的文献

Advances in the structures, mechanisms and targeting of molecular chaperones.

Signal Transduct Target Ther. 2025 Mar 12;10(1):84. doi: 10.1038/s41392-025-02166-2.

Design, Synthesis, and Biological Evaluation of Chiral-Proline Derivatives as Novel HSP90 Inhibitors.

ACS Med Chem Lett. 2025 Jan 22;16(2):301-310. doi: 10.1021/acsmedchemlett.4c00550. eCollection 2025 Feb 13.

Thermal Titration Molecular Dynamics: The Revenge of the Fragments.

J Chem Inf Model. 2025 Feb 10;65(3):1492-1513. doi: 10.1021/acs.jcim.4c01681. Epub 2025 Jan 21.

Discovery of new Hsp90-Cdc37 protein-protein interaction inhibitors: screening and optimization of anticancer activity.

RSC Adv. 2024 Sep 5;14(39):28347-28375. doi: 10.1039/d4ra05878j. eCollection 2024 Sep 4.

Targeted delivery of HSP90 inhibitors for efficient therapy of CD44-positive acute myeloid leukemia and solid tumor-colon cancer.

J Nanobiotechnology. 2024 Apr 22;22(1):198. doi: 10.1186/s12951-024-02460-1.

Intrinsic Solubility of Ionizable Compounds from p Shift.

ACS Omega. 2023 Nov 13;8(47):44571-44577. doi: 10.1021/acsomega.3c04071. eCollection 2023 Nov 28.

Cascade Transformation of the Ansamycin Benzoquinone Core into Benzoxazole Influencing Anticancer Activity and Selectivity.

J Org Chem. 2023 Jul 7;88(13):9469-9474. doi: 10.1021/acs.joc.3c00493. Epub 2023 Jun 5.

The chaperone system in cancer therapies: Hsp90.

J Mol Histol. 2023 Apr;54(2):105-118. doi: 10.1007/s10735-023-10119-8. Epub 2023 Mar 18.

Impact of Co-chaperones and Posttranslational Modifications Toward Hsp90 Drug Sensitivity.

Subcell Biochem. 2023;101:319-350. doi: 10.1007/978-3-031-14740-1_11.

HSP90 inhibitors and cancer: Prospects for use in targeted therapies (Review).

Oncol Rep. 2023 Jan;49(1). doi: 10.3892/or.2022.8443. Epub 2022 Nov 11.